Literature DB >> 12682240

A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells.

Sandip K Datta1, Vanessa Redecke, Kiley R Prilliman, Kenji Takabayashi, Maripat Corr, Thomas Tallant, Joseph DiDonato, Roman Dziarski, Shizuo Akira, Stephen P Schoenberger, Eyal Raz.   

Abstract

Dendritic cells (DCs) are capable of cross-presenting exogenous Ag to CD8(+) CTLs. Detection of microbial products by Toll-like receptors (TLRs) leads to activation of DCs and subsequent orchestration of an adaptive immune response. We hypothesized that microbial TLR ligands could activate DCs to cross-present Ag to CTLs. Using DCs and CTLs in an in vitro cross-presentation system, we show that a subset of microbial TLR ligands, namely ligands of TLR3 (poly(inosinic-cytidylic) acid) and TLR9 (immunostimulatory CpG DNA), induces cross-presentation. In contrast to presentation of Ag to CD4(+) T cells by immature DCs, TLR-induced cross-presentation is mediated by mature DCs, is independent of endosomal acidification, and relies on cytosolic Ag processing machinery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12682240     DOI: 10.4049/jimmunol.170.8.4102

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  109 in total

1.  Enhanced antigen processing of flagellin fusion proteins promotes the antigen-specific CD8+ T cell response independently of TLR5 and MyD88.

Authors:  John T Bates; Aaron H Graff; James P Phipps; Jason M Grayson; Steven B Mizel
Journal:  J Immunol       Date:  2011-04-22       Impact factor: 5.422

2.  Dendritic cells continue to capture and present antigens after maturation in vivo.

Authors:  Scott B Drutman; E Sergio Trombetta
Journal:  J Immunol       Date:  2010-07-19       Impact factor: 5.422

3.  Differential ability of surface and endosomal TLRs to induce CD8 T cell responses in vivo.

Authors:  Rajakumar Mandraju; Sean Murray; James Forman; Chandrashekhar Pasare
Journal:  J Immunol       Date:  2014-03-31       Impact factor: 5.422

4.  Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.

Authors:  Max A Cheng; Emily Farmer; Claire Huang; John Lin; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2018-03-16       Impact factor: 5.695

5.  Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2.

Authors:  Tomoko Hayashi; Michael Chan; John T Norton; Christina C N Wu; Shiyin Yao; Howard B Cottam; Rommel I Tawatao; Maripat Corr; Dennis A Carson; Gregory A Daniels
Journal:  Melanoma Res       Date:  2011-02       Impact factor: 3.599

Review 6.  Induction of antigen cross-presentation by Toll-like receptors.

Authors:  Sandip K Datta; Eyal Raz
Journal:  Springer Semin Immunopathol       Date:  2004-10-14

7.  MyD88 expression is required for efficient cross-presentation of viral antigens from infected cells.

Authors:  Margaret Chen; Christina Barnfield; Tanja I Näslund; Marina N Fleeton; Peter Liljeström
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

8.  MHC class I and II peptide homology regulates the cellular immune response.

Authors:  Matthew M Halpert; Vanaja Konduri; Dan Liang; Jonathan Vazquez-Perez; Colby J Hofferek; Scott A Weldon; Yunyu Baig; Indira Vedula; Jonathan M Levitt; William K Decker
Journal:  FASEB J       Date:  2020-04-16       Impact factor: 5.191

9.  Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation.

Authors:  Nicholas M Molino; Amanda K L Anderson; Edward L Nelson; Szu-Wen Wang
Journal:  ACS Nano       Date:  2013-10-09       Impact factor: 15.881

10.  Inhibition of experimental asthma by indoleamine 2,3-dioxygenase.

Authors:  Tomoko Hayashi; Lucinda Beck; Cyprian Rossetto; Xing Gong; Osamu Takikawa; Kenji Takabayashi; David H Broide; Dennis A Carson; Eyal Raz
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.